These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33840305)

  • 1. Detecting and Reporting Deceptive Prescription Drug Promotion: Differences Across Consumer and Physician Audiences and by Number and Type of Deceptive Claims and Tactics.
    Betts KR; O'Donoghue AC; Johnson M; Boudewyns V; Paquin RS
    Health Commun; 2022 Nov; 37(13):1609-1621. PubMed ID: 33840305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental evidence of consumer and physician detection and rejection of misleading prescription drug website content.
    Boudewyns V; Betts KR; Johnson M; Paquin RS; O'Donoghue AC; Southwell BG
    Res Social Adm Pharm; 2021 Apr; 17(4):733-743. PubMed ID: 32792323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Awareness of the Food and Drug Administration's Bad Ad Program and Education Regarding Pharmaceutical Advertising: A National Survey of Prescribers in Ambulatory Care Settings.
    O'Donoghue AC; Boudewyns V; Aikin KJ; Geisen E; Betts KR; Southwell BG
    J Health Commun; 2015; 20(11):1330-6. PubMed ID: 26176326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H
    Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Wanasika I
    Int J Health Policy Manag; 2016 Mar; 5(6):391-2. PubMed ID: 27285519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the FDA's oversight of direct-to-consumer advertising.
    Gahart MT; Duhamel LM; Dievler A; Price R
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Rollins BL
    Int J Health Policy Manag; 2016 Feb; 5(4):287-8. PubMed ID: 27239875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration.
    Sullivan HW; Aikin KJ; Chung-Davies E; Wade M
    PLoS One; 2016; 11(5):e0155035. PubMed ID: 27149513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs.
    Faerber AE; Kreling DH
    J Gen Intern Med; 2014 Jan; 29(1):110-8. PubMed ID: 24030427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What influences healthcare providers' prescribing decisions? Results from a national survey.
    Price SM; O'Donoghue AC; Rizzo L; Sapru S; Aikin KJ
    Res Social Adm Pharm; 2021 Oct; 17(10):1770-1779. PubMed ID: 33558154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The federal regulation of prescription drug advertising and promotion.
    Kessler DA; Pines WL
    JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.
    Adams C
    J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A scoping review of empirical research on prescription drug promotion.
    Giombi K; Thompson J; Wines C; Haughney R; Sullivan HW; Betts KR
    Res Social Adm Pharm; 2023 Jun; 19(6):859-872. PubMed ID: 36931982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.
    Klara K; Kim J; Ross JS
    J Gen Intern Med; 2018 May; 33(5):651-658. PubMed ID: 29484575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay.
    Aikin KJ; Southwell BG; Paquin RS; Rupert DJ; O'Donoghue AC; Betts KR; Lee PK
    Res Social Adm Pharm; 2017; 13(2):378-388. PubMed ID: 27178746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers.
    Findlay SD
    Pharmacoeconomics; 2001; 19(2):109-19. PubMed ID: 11284378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation.
    Li S; Gibbs I
    J Pharm Pharm Sci; 2021; 24():381-389. PubMed ID: 34314671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Southwell BG; Rupert DJ
    Int J Health Policy Manag; 2016 Jan; 5(3):211-3. PubMed ID: 26927597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promotion of prescription drugs to consumers.
    Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
    N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.